These benefits, together with a prior report demonstrating that a small-molecule ACKR3 agonist CCX771 displays anxiolytic-like behavior in mice,2 help the strategy of targeting ACKR3 as a novel approach to modulate the opioid program, which could open up new therapeutic avenues for opioid-similar Conditions. It can even be legally https://aristotlew949qgb2.blogdal.com/profile